|
|
Post by mnkdfann on May 16, 2019 15:13:02 GMT -5
"Mannkind Announces Distribution Agreement in Australia" I'm waiting for the 4th thread with this same title before I believe this.  |
|
|
|
Post by mnkdfann on May 15, 2019 11:18:02 GMT -5
Imo, Mannkind doesn't depend at all on retail investors for cash. In fact, retail investor financial concerns are routinely sacrificed in order to raise money from the valued investors. MNKD does depend on retail investors for its cash, albeit indirectly. Mannkind and most companies of its size finance via PIPE transactions where the investment bank sells shares to a handful of hedge funds at a discount (often with warrants) and those hedge funds sell their discounted shares back to the market. The success of the strategy depends on retail investors willing to soak up the new liquidity as so long as there are lots of retail holders willing to average down or making comments like "I am going to pick up a few thousand more shares at these cheap prices" then all is well. When retail decides that averaging down is not a good strategy or when retail portfolios get so overloaded with MNKD that retail stops buying more, then the hedge funds will have nowhere to offload their newly acquired stock. Hedge funds are stock churners, not long-term stock holders. That means the end of PIPE funding and the start of 100% reliance on Rule 415 transactions which are even more dilutive. The switch to 415 offerings is usually the beginning of the end for a biotech. I agree with the 'indirectly' part. But (again, imo) the valued investors are the ones Mannkind really cares about when it comes to financing and raising cash. Regarding one point you made, don't banks and hedge funds also offload shares to pension plan funds and such? That is, don't they have more pigeons available than just the retail investors to offload shares onto? |
|
|
|
Post by mnkdfann on May 15, 2019 9:53:49 GMT -5
I get the impression that Mike is sick to death of retail investors complaining. That is why he locked Twitter.. Yesterday's ASM was in direct response to that. Didn't seem like there was the same fanfare as previous years. Mike hasn't visited PB since April 9. He used to be here every couple of days and would occasionally post here. In the grand scheme of things we retail investors really have no say about anything. And it seems to me management isn't listening to us anymore. They are going to do their jobs the way they feel is best. We can pound the tables everyday with our opinions as we have for years, not sure it will make any difference. I believe that is the message being sent from management to retail investors. But please keep your wallets open when we come back to the table for more cash...  Imo, Mannkind doesn't depend at all on retail investors for cash. In fact, retail investor financial concerns are routinely sacrificed in order to raise money from the valued investors. |
|
|
|
Post by mnkdfann on May 14, 2019 10:10:24 GMT -5
At least we know who wants to be the front runner and the next round of financing Who? I see no name attached to it, and its price target looks different than what was reported for BTIG. |
|
|
|
Post by mnkdfann on May 14, 2019 8:34:07 GMT -5
"MannKind (NASDAQ:MNKD) initiated with Buy rating and $3 (144% upside) price target at BTIG Research citing peak sales of more than $350M for Afrezza. Analyst Robert Hazlett also likes the potential upside with technosphere programs in migraine, cystic fibrosis and cannabinoids. Shares up 10% premarket." (From SA.) is BTIG legit? It's legit. Not sure how well regarded it is, but it is a solid international investment bank. www.btig.com/And it looks like the analyst isn't a total tool (unlike some analysts who have covered MNKD in the past) when you look at performance since 2009. www.tipranks.com/analysts/robert-hazlettlinkedin.com/in/robert-bert-hazlett-59455a34 Although his recent record is more hit or miss, he is still a superstar when you compare his history with MK's. |
|
|
|
Post by mnkdfann on May 14, 2019 7:52:34 GMT -5
"MannKind (NASDAQ:MNKD) initiated with Buy rating and $3 (144% upside) price target at BTIG Research citing peak sales of more than $350M for Afrezza. Analyst Robert Hazlett also likes the potential upside with technosphere programs in migraine, cystic fibrosis and cannabinoids. Shares up 10% premarket."
(From SA.)
|
|
|
|
Post by mnkdfann on May 13, 2019 13:52:41 GMT -5
@natesnotes thanks. You speak of the retail mood quite accurately. For me, at 90% down and from a risk/reward point of view, there is almost no personal reward to reduce or scale out of my position. I would almost feel a sense of closure in the event of bk and total $250k/100% loss. For the last 5 years we've seen highest market gains in history, meanwhile I parked all my liquid assets in this. My bad, on many fronts, I know. Two questions to follow on your inter-issue if you feel inclined to respond. 1- Are you satisfied with the marketing effort so far and 2- How do you intend (or did you) to vote for this year's proxy? Again, thank you for keeping with this. Sincerely Nate... sparkrov I’ll be providing an update of my thoughts re: $MNKD in the May issue when it comes out next weekend... thanks for the interest! Those that want MNKD to fail are always looking for the next shoe to drop that can be presented by them in in the worst possible way. If Nate decides to scale back, no matter how he explains it - that will be just one more thing. Hope that does not happen any time soon. If Nate were to scale back at these levels, I don't see how that could be presented as other than a negative no matter how he explains it. |
|
|
|
Post by mnkdfann on May 13, 2019 10:23:15 GMT -5
|
|
|
|
Post by mnkdfann on May 13, 2019 8:13:26 GMT -5
The SEC documents I've looked at say nothing about it being callable.
But even so, I can't see Deerfield complaining were Mannkind to propose payment in advance in cash. Anything is negotiable.
|
|
|
|
Post by mnkdfann on May 12, 2019 15:08:37 GMT -5
We are using different definitions... not a big deal. I’d consider 5% of the mealtime insulin market niche. Management called Afrezza a “premium” product on the last call. That’s probably referring to the price of Afrezza. Sometimes niche products can be highly profitable, but not this time... I’m going to bang my head against “if only Afrezza had price parity” forever in how we got to this point. ............ Definition “A niche market is the subset of the market on which a specific product is focused. The market niche defines the product features aimed at satisfying specific market needs, as well as the price range, production quality and the demographics that it is intended to target. It is also a small market segment.” By the very definition you posted it tells you Afrezza is not a "niche product"....the approval for the entire market of PWD is not a small market segment, it is intended for all demographics (peds to follow) and it's for all mealtime needs and then some. It is not intended nor focused on any subset of the market rather the entire market which it was intended to serve and that is all PWD. It could be described as a niche drug in that its unique delivery system appeals to only a small specific portion of that market. |
|
|
|
Post by mnkdfann on May 11, 2019 20:00:01 GMT -5
You see, this close to kissing 50 years on this planet, 1)I've finally got the patience I should have had in my youth. 2) I'm playing with mad money that I can walk away from without feeling too bad. 3)In 20 years of personal investing, I've already made all the mistakes a person can make. Ive been guilty of chasing a stock, catching a falling knife, going against a trend, falling in love with a stock(of which, I fear many here are guilty) I've sold too early, I've sold too late, I've not bought when I should have, I've bought when I shouldn't etc. etc. etc. you get my point. However, I've learned from my failures as much as my successes. Perspective counts. Honestly, most people invested in MNKD have probably experience most if not all of those. I mean, with just the MNKD stock alone. |
|
|
|
Post by mnkdfann on May 11, 2019 19:15:22 GMT -5
So what is the other corporate business that is going on in the city? Rose's response doesn't really make sense to me. So this corporate business in NYC is going on simultaneously with the ASM? Like, they overlap? Otherwise, I don't see why they couldn't have easily scheduled the meeting for one of the other two locations as per usual. Perhaps someone important and based in NYC (a financier, or a representative of a new partner) is attending the ASM, and the meeting was moved to NYC to accommodate that person? Otherwise, Rose's explanation sounds like an weak excuse to me. |
|
|
|
Post by mnkdfann on May 11, 2019 6:00:24 GMT -5
Let me answer for him. None of your business. Thanks, very helpful. Seriously, though, he brings this up often enough (multiple times a month, if not per week) that I do not think it off base to ask for further details. I mean no harm or anything, his repeated posts just prompted my curiousity. And, as I already said, he can do / invest as he likes. |
|
|
|
Post by mnkdfann on May 10, 2019 22:17:46 GMT -5
The magic of reverse splits? Anyway, you can invest your money for your daughters however you like. MNKD all the way, who am I to say otherwise? I'm just curious, how many shares of MNKD are enough, and do you ever invest them in any other stock(s)? From what you post here, it sounds like their future is very heavily dependent on the success of this one company. |
|
|
|
Post by mnkdfann on May 10, 2019 19:53:51 GMT -5
I was at the pharmacy the other day, and the pharmacist I spoke to (one of several in the pharmacy) happened to be someone who mentioned to me in passing that she was transiting into a diabetes educator.
I thought I would ask her about what she advises clients, etc. I asked whether she had heard of an inhaled insulin, or about insulin pills in development. She was excited to hear about both, but this was all news to her.
FWIW, this was in Canada where Afrezza is not on the market. But I thought as a diabetes educator she would be up on what is current.
As to the question "Are you still a MNKD believer?" ... I do believe that Afrezza will survive in some form. AFAIK, the science is sound. But as for the Mannkind corporation, I really don't know. I have some doubts.
I was once invested in a world class asset, worth billions. But the financial crisis hit, and it had to sell out to a better funded competitor for pennies on the dollar. Believe me, I never imagined such a thing happening. So I am cautions when it comes to MNKD, and I did sell my last shares around $1.80 some months ago. If I ever buy back in, it will only be a small investment.
|
|
